Evidence map›Paper›PMID 32774592›Full record

ArticleThe Pan African medical journal2020

Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report.

Mohammad Bader Obeidat, Ali Mohammad Al-Swailmeen, Abdulmajeed Mohammad Arabeat, Ayman Sulaiman Abukamar

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Pan African medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mohammad Bader ObeidatDepartment of Medicine, Hematology and Oncology Unit, King Hussein Medical City, Amman, Jordan.
Ali Mohammad Al-SwailmeenDepartment of Medicine, Hematology and Oncology Unit, King Hussein Medical City, Amman, Jordan.
Abdulmajeed Mohammad ArabeatDepartment of Medicine, Hematology and Oncology Unit, King Hussein Medical City, Amman, Jordan.
Ayman Sulaiman AbukamarDepartment of Medicine, Hematology and Oncology Unit, King Hussein Medical City, Amman, Jordan.
King Hussein Medical Center · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma cell leukemia represents the most aggressive form of plasma cell dyscrasia. We report a 67-year old male with no previous medical illnesses presented with anemic symptoms. Blood film revealed 35% circulating plasma cells, bone marrow biopsy showed plasma cells constituting 85%. Diagnosis of primary plasma cell leukemia was completed. Induction chemotherapy with bortezomib, doxorubicin, and dexamethasone was started. After the first cycle, plasma cells in peripheral blood disappeared. The patient had complete remission at evaluation after the third cycle. Re-evaluation after the sixth cycle showed that he maintained remission. As he was non-transplant eligible, he was we kept on maintenance bortezomib. Twenty-four months after the diagnosis, the patient remains in remission.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDoxorubicinFollow-Up StudiesHumansLeukemia, Plasma CellMaleRemission InductionBortezomibDexamethasoneDoxorubicinbortezomibmultiple myelomaPlasma cell leukemia

Identifiers

PMID32774592
PMCPMC7388633
OpenAlexW3025242810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.